Navigation Links
Forest Laboratories, Inc. and Merz Pharma GmbH & Co. KgaA File Additional Lawsuit Against Several Companies for Patent Infringement
Date:1/25/2008

NEW YORK, Jan. 25 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX), Forest Laboratories Holdings, Ltd., Merz Pharma GmbH & Co. KgaA, and Merz Pharmaceuticals GmbH announced that they have filed a second lawsuit in the U.S. District Court for the District of Delaware against additional companies for infringement of U.S. Patent No. 5,061,703 (the '703 patent), which relates to Forest's Namenda(R) product. The defendants named in the lawsuit include Dr. Reddy's Laboratories Limited, Genpharm Inc., Interpharm Inc., Mylan Pharmaceuticals Inc., Ranbaxy Laboratories Limited, Sun India Pharmaceutical Industries Limited, and related companies and subsidiaries thereof. The '703 patent expires in April 2010. Forest has applied for patent term extension which, if granted, would extend the '703 patent until September 2013.

(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )

As previously reported, Forest and Merz had received notification from several companies that they had filed Abbreviated New Drug Applications with Paragraph IV certifications to obtain approval to market generic versions of Namenda and commenced an action in patent infringement in the U.S. District Court in Delaware against such filers.

Except for the historical information contained herein, this release contains forward-looking statements within the meaning of the Private Securities Litigation Reform act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in each of Forest Laboratories' Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and any subsequent SEC filings.


'/>"/>
SOURCE Forest Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Forest and Cypress Announce Submission of New Drug Application for Milnacipran for the Treatment of Fibromyalgia Syndrome
2. BioSpace Launches 3rd Edition of BioForest(TM) Bioscience Marketing Campaign
3. Drugs from Johnson & Johnson/Basilea and Forest Are the Most Promising Antibiotics in the Community-Acquired Pneumonia Pipeline
4. Nanotube forests grown on silicon chips for future computers, electronics
5. Forest Laboratories Lexapro and Generics-Dominated Fluoxetine Lead First-Line Therapy in the Treatment for Major Depression
6. Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
7. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Methimazole Tablets USP, 5 mg and 10 mg
9. Octapharma Joins Biotechnology Industry Organization
10. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
11. Aton Pharma Introduces Expanded Distribution of Lacrisert(R) (hydroxypropyl cellulose ophthalmic insert) at Hawaiian Eye
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... (PRWEB) , ... December 02, 2016 , ... ... innovative U.S.-owned and -operated small businesses in federally funded research and development is ... international society for optics and photonics . , As part of the National ...
(Date:12/4/2016)... 3, 2016  In five studies being presented today ... Meeting and Exposition in San Diego ... improve the delivery of life-saving treatments to patients with ... designed to carry therapies directly to the sites in ... provide a substantial advantage over traditional, systemic methods. The ...
(Date:12/2/2016)... ... December 02, 2016 , ... In anticipation ... and lumbar disc production, company President, Jake Lubinski will be traveling to Switzerland ... AxioMed disc in Bern, Lucerne, and Zurich to discuss the benefits of a ...
(Date:12/2/2016)... , Dec. 2, 2016  The Multiple Myeloma ... from the MMRF CoMMpass Study SM —the largest and ... precision medicine in multiple myeloma—will be presented at the ... Meeting & Exposition in San Diego ... to optimize treatment strategies, as well as identify pathways ...
Breaking Biology Technology:
(Date:11/17/2016)... Global Market Watch: Primarily supported by ownership types; ... Academics) market is to witness a value of US$37.1 billion ... Compounded Annual Growth Rate (CAGR) of 10.75% is foreseen from ... 2014-2020. North America is not way ... Europe at 9.56% respectively. Report Focus: ...
(Date:11/14/2016)... Fla., Nov. 14, 2016  xG Technology, Inc. ("xG" ... providing critical wireless communications for use in challenging operating ... September 30, 2016. Management will hold a conference call ... 5:00 p.m. Eastern Time (details below). Key ... a $16 million binding agreement to acquire Vislink Communication ...
(Date:6/22/2016)... -- On Monday, the Department of Homeland Security (DHS) ... for the Biometric Exit Program. The Request for Information ... explains that CBP intends to add biometrics to confirm ... States , in order to deter visa overstays, ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
Breaking Biology News(10 mins):